open access
Diagnostic and treatment dilemmas in case of the severe course of multicentric Castleman disease
Affiliations- Gdański Uniwersytet Medyczny
- Department of Hematology and Transplantology, Medical University of Gdansk, SMOLUCHOWSKIEGO 17 Gdańsk, 80-214 Gdansk, Poland
- Department of Pathomorfology, Medical University of Gdańsk, SMOLUCHOWSKIEGO 17 Gdańsk, 80-214 Gdansk, Poland
- Department of Hematology and Transplantology, Medical University of Gdansk, SMOLUCHOWSKIEGO 17 Gdańsk, 80-214 Gdansk, Poland
open access
Abstract
Abstract
Keywords
multicentric Castleman disease, TAFRO
About this articleTitle
Diagnostic and treatment dilemmas in case of the severe course of multicentric Castleman disease
Journal
Issue
Article type
Clinical vignette
Pages
601-603
Published online
2021-11-08
Page views
2944
Article views/downloads
173
DOI
10.5603/AHP.2021.0100
Bibliographic record
Acta Haematol Pol 2021;52(6):601-603.
Keywords
multicentric Castleman disease
TAFRO
Authors
Michalina Tamowicz
Agnieszka Piekarska
Michał Kunc
Magdalena Dutka
Ewa Zarzycka
Wojciech Biernat
Maria Bieniaszewska
Jan Maciej Zaucha
References (10)- Castleman B, Iverson L, Menendez V. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956; 9(4): 822–830, doi: 10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4.
- Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978; 69(1): 86–90.
- Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998; 128(8): 657–662.
- Fajgenbaum DC, Shilling D. Castleman disease pathogenesis. Hematol Oncol Clin North Am. 2018; 32(1): 11–21.
- Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014; 123(19): 2924–2933.
- Kojima M, Motoori T, Asano S, et al. Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients. Pathol Res Pract. 2007; 203(6): 423–431.
- Kojima M, Motoori T, Nakamura S. Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients. Biomed Pharmacother. 2006; 60(10): 663–672.
- Fajgenbaum DC, Uldrick T, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. Blood. 2017; 129(12): 1646–1657.
- Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013; 53(1): 57–61.
- Wang HW, Pittaluga S, Jaffe ES. Multicentric Castleman disease: where are we now? . Semin Diagn Pathol. 2016; 33(5): 294–306.